99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer

This exploratory study conducted under the RDRC program studies the biodistribution of 99mTc-PSMA-I\&S in patients with prostate cancer who undergo pelvic lymph node dissection. Prostate specific membrane antigen (PSMA)-targeted radio-guided surgery uses the preoperative intravenous administration of a PSMA-ligand called PSMA-imaging and surgery (I\&S) labeled with the gamma-emitter radioisotope Technetium-99m (99mTc). Giving 99mTc-PSMA-I\&S may detect PSMA-expressing lymph nodes during surgery using a gamma probe and may help guide doctors to detect prostate cancer that has spread to the lymph nodes.

NCT Number	NCT04857502
Lead Sponsor	Jonsson Comprehensive Cancer Center
Conditions	Prostate Carcinoma, Recurrent Prostate Carcinoma
Enrollment	30 participants
Start Date	2021-04-27
Primary Completion	2027-06-01 (estimated)
Study Completion	2028-06-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-17